Citations

Clear

904 citation(s) found for "Gordon, S".

High-Frequency Oscillation for Adult Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis
Goligher, Ewan C. , Adhikari, Neill K. J. , Meade, Maureen O. , Wunsch, Hannah , Amato, Marcelo B. P. , Ferguson, Niall D. , Rubenfeld, Gordon D., Munshi, Laveena , Hodgson, Carol Lynette , Uleryk, Elizabeth M. , Gajic, Ognjen , Fan, Eddy

Mayo Clinic

Annals of the American Thoracic Society | October 18, 2017 | Volume: 14 | Issue: Supplement_4 | Pages: S289-S296

10.1513/annalsats.201704-341ot | PMID 29043832 Get It

Abstract Rationale By minimizing tidal lung strain and maintaining alveolar recruitment, high-frequency oscillatory ventilation (HFOV) may protect against ventilator-induced lung injury. Objectives To summarize the current evidence in support of the use of HFOV in adult patients with acute respiratory distress syndrome. Methods We conducted a systematic review and meta-analysis of randomized trials comparing mortality rates with the use of HFOV versus conventional mechanical ventilation for adult patients with acute respiratory distress syndrome. Eligible trials were identified from previously published systematic reviews and an updated literature search. Data on 28-day mortality, oxygenation, adverse events, and use of rescue therapies were collected; effects were pooled using random effects models weighted by inverse variance. Strength of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation methodology. Results Six trials were eligible for inclusion (total n = 1,715 patients). Four trials mandated lung-protective ventilation in the control group and one trial applied a higher positive end-expiratory pressure (PEEP) ventilation strategy in the control group. None of the trials were judged to be at high risk of bias, though all were unblinded. In trials that did not systematically employ any cointerventions with HFOV and that targeted low tidal volumes in the patients randomized to conventional ventilation (primary analysis), HFOV had no significant effect on mortality (three trials; risk ratio [RR], 1.14; 95% confidence interval [CI], 0.88 to 1.48; evidence grade = high). Pooled analysis of all six trials also did not suggest a significant mortality reduction (RR, 0.94; 95% CI, 0.71 to 1.24; evidence grade = low). The single trial that employed a conventional ventilation strategy with both lower tidal volumes and higher PEEP as control reported higher mortality in patients receiving HFOV (RR, 1.41; 95% CI, 1.12 to 1.79). HFOV was not associated with improved oxygenation after 24 hours (five trials; mean increase of 10 mm Hg; 95% CI, −16 to 37 mm Hg). Rates of barotrauma were not different between HFOV and conventional ventilation, although significant benefit or harm could not be excluded (RR, 1.15; 95% CI, 0.61 to 2.17). Conclusions Published randomized trials suggest that HFOV is not associated with a mortality benefit, and may even be harmful in comparison to ventilation with low tidal volumes and higher levels of PEEP.
Lung Recruitment Maneuvers for Adult Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis
Goligher, Ewan C. , Adhikari, Neill K. J. , Meade, Maureen O. , Wunsch, Hannah , Amato, Marcelo B. P. , Ferguson, Niall D. , Rubenfeld, Gordon D., Hodgson, Carol Lynette , Uleryk, Elizabeth M. , Gajic, Ognjen , Fan, Eddy

Mayo Clinic

Annals of the American Thoracic Society | October 18, 2017 | Volume: 14 | Issue: Supplement_4 | Pages: S304-S311

10.1513/annalsats.201704-340ot | PMID 29043837 Get It

Abstract Rationale In patients with acute respiratory distress syndrome (ARDS), lung recruitment maneuvers (LRMs) may prevent ventilator-induced lung injury and improve survival. Objectives To summarize the current evidence in support of the use of LRMs in adult patients with ARDS and to inform the recently published American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine clinical practice guideline on mechanical ventilation in ARDS. Methods We conducted a systematic review and meta-analysis of randomized trials comparing mechanical ventilation strategies with and without LRMs. Eligible trials were identified from among previously published systematic reviews and an updated literature search. Data on 28-day mortality, oxygenation, adverse events, and use of rescue therapy were collected, and results were pooled using random effects models weighted by inverse variance. Strength of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Results We screened 430 citations and previous systematic reviews and found six trials eligible for inclusion (n = 1,423 patients in total). The type of LRM varied widely between trials, and five of the trials involved a cointervention with a higher positive end-expiratory pressure (PEEP) ventilation strategy. Risk of bias was deemed high in one trial. In the primary analysis, the only trial without a cointervention showed that LRMs were associated with reduced mortality (one trial; risk ratio [RR], 0.62; 95% confidence interval [CI], 0.39–0.98; evidence grade = low). Meta-analysis of all six trials also suggested a significant mortality reduction (six trials; RR, 0.81; 95% CI, 0.69–0.95; evidence grade = moderate), and the use of a higher PEEP cointervention did not significantly modify the mortality effect (P = 0.27 for heterogeneity). LRMs were also associated with improved oxygenation after 24 hours (six trials; mean increase, 52 mm Hg; 95% CI, 23–81 mm Hg) and less frequent requirement for rescue therapy (three trials; RR, 0.65; 95% CI, 0.45–0.94). LRMs were not associated with an increased rate of barotrauma (four trials; RR, 0.84; 95% CI, 0.46–1.55). The rate of hemodynamic compromise was not significantly increased with LRMs (three trials; RR, 1.30; 95% CI, 0.92–1.78). Conclusions Randomized trials suggest that LRMs in combination with a higher PEEP ventilation strategy reduce mortality, but confidence in this finding is limited. Further trials are required to confirm benefit from LRMs in adults with ARDS.
Comprehensive Characterization of Alternative Polyadenylation in Human Cancer
Xiang, Yu , Ye, Youqiong , Lou, Yanyan , Zhang, Zhao , Chen, Ning-Yuan, Kim, Yoon-Jin , Ozguc, Fatma Muge, Diao, Lixia , Xia, Yang, Kellems, Rodney E. , Shyu, Ann‐Bin, Mills, Gordon B. , Han, Leng , Ye, Youqiong , Han, Leng , Mills, Gordon B , Yang, Yang , Cai, Chunyan C. , Mills, Tingting , Chen, Ning‐Yuan, Karmouty‐Quintana, Harry , Xia, Yang, Chen, Zheng , Blackburn, Michael R. , Yoo, Seung Hee

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 25, 2017 | Volume: 110 | Issue: 4 | Pages: 379-389

10.1093/jnci/djx223 | PMID 29106591 Get It

Considering health equity when moving from evidence-based guideline recommendations to implementation: a case study from an upper-middle income country on the GRADE approach
Eslava‐Schmalbach, Javier , Mosquera, Paola A. , Álzate, Juan Pablo , Jull, Janet , Katikireddi, Srinivasa Vittal , Morton, Rachel L, Thabane, Lehana , Shea, Bev , Singh, Jasvinder A. , Flórez, Iván D. , Schünemann, Holger J. , Singh, Jasvinder, Singh, Jasvinder A , Schünemann, Holger J , Thabane, Lehana , Pottie, Kevin , Welch, Vivian Andrea , Akl, Elie A. , Lang, Eddy , Stein, Aírton Tetelbom , Guyatt, Gordon , Tugwell, Peter

Mayo Clinic

Health Policy and Planning | August 26, 2017 | Volume: 32 | Issue: 10 | Pages: 1484-1490

10.1093/heapol/czx126 | PMID 29029068 Get It

Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching*
Trauer, James M. , Muhi, Stephen , McBryde, Emma S. , Harbi, Shmeylan Al, Arabi, Yaseen M. , Boyle, Andrew , Cartin‐Ceba, Rodrigo , Chen, Yung‐Tai , Gajić, Ognjen, Godsell, Jack , Gong, Michelle N. , Kor, Daryl J. , Lösche, Wolfgang, McAuley, Daniel F. , O’Neal, Hollis R. , Otto, Gordon P , Soßdorf, Maik, Tsai, Min-Juei, Valerio-Rojas, Juan Carlos , Poll, Tom van der , Ware, Lorraine B. , Widmer, Andreas F. , Wiewel, Maryse A. , Winning, Johannes, Eisen, Damon P. , Trauer, James, Harbi, Shmeylan A. Al , Chen, Wei, Falcone, Marco , Gajic, Ognjen , Osthoff, Michael Friedrich , Violi, Francesco , Arabi, Yaseen M

Mayo Clinic

Critical Care Medicine | August 10, 2017 | Volume: 45 | Issue: 11 | Pages: 1871-1879

10.1097/ccm.0000000000002654 | PMID 28799949 Get It

Objective: The primary objective was to conduct a meta-analysis on published observational cohort data describing the association between acetyl-salicylic acid (aspirin) use prior to the onset of sepsis and mortality in hospitalized patients. Study Selection: Studies that reported mortality in patients on aspirin with sepsis with a comparison group of patients with sepsis not on prior aspirin therapy were included. Data Sources: Fifteen studies described hospital-based cohorts (n = 17,065), whereas one was a large insurance-based database (n = 683,421). Individual-level patient data were incorporated from all selected studies. Data Extraction: Propensity analyses with 1:1 propensity score matching at the study level were performed, using the most consistently available covariates judged to be associated with aspirin. Meta-analyses were performed to estimate the pooled average treatment effect of aspirin on sepsis-related mortality. Data Synthesis: Use of aspirin was associated with a 7% (95% CI, 2–12%; p = 0.005) reduction in the risk of death as shown by meta-analysis with considerable statistical heterogeneity (I 2 = 61.6%). Conclusions: These results are consistent with effects ranging from a 2% to 12% reduction in mortality risk in patients taking aspirin prior to sepsis onset. This association anticipates results of definitive studies of the use of low-dose aspirin as a strategy for reduction of deaths in patients with sepsis.
Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Konstantinopoulos, Panagiotis A. , Barry, William T., Birrer, Michael J. , Farooq, Sarah , Cadoo, Karen A. , Whalen, Christin, Luo, Weixiu, Liu, Hui , Aghajanian, Carol , Taylor, Barry S. , Won, Helen , Palakurthi, Sangeetha , Cantley, Lew, D’Andrea, Alan D. , Matulonis, Ursula A. , Westin, Shannon N , Solit, David B. , Mills, Gordon B. , Berger, Michael , Liu, Joyce F. , Kaufmann, Scott H. , Swisher, Elizabeth M. , Winer, Eric P. , Wulf, Gerburg M. , Konstantinopoulos, Panagiotis A , D'Andrea, Alan

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: CT008-CT008

10.1158/1538-7445.am2017-ct008 Get It

Abstract Background: In vivo synergy with concurrent PI3-Kinase inhibition and PARP inhibition has been observed in BRCA-deficient and BRCA-proficient preclinical models of triple negative breast cancer (TNBC) and ovarian cancer (OC). A phase I trial of the oral pan-class I PI3-Kinase inhibitor BKM120 and the PARP inhibitor olaparib demonstrated anti-cancer activity in TNBC and OC, both in patients with and without germline BRCA1 and BRCA2 (BRCA) mutations. However, CNS toxicity (depression) and liver function test abnormalities limited dose escalation of BKM120 prompting evaluation of the alpha specific PI3-Kinase inhibitor BYL719 (which has no CNS toxicity) in combination with olaparib. Methods: Olaparib was administered twice daily (tablet formulation) and BYL719 daily on a 28-day cycle, both orally. A 3 + 3 dose-escalation design was employed with primary objectives of defining the maximum tolerated dose (MTD) and recommended phase 2 dose of the combination of BYL719 and olaparib, and secondary objectives of defining toxicity, activity, and pharmacokinetic profiles of both agents. Eligibility included recurrent TNBC or high grade serous (HGS) OC, or any histology OC or breast cancer (BC) with presence of a known germline BRCA mutation, performance status of 0-1 and measurable/evaluable cancer. Patients with platinum sensitive or resistant or refractory OC were eligible and prior PARP inhibitor use was allowed. Dose-expansion cohorts at the MTD were enrolled for both BC and OC. Results: 46 patients (16 BC and 30 OC) have been enrolled in the study; 28 patients participated in the dose escalation portion of the study (4 BC and 24 OC). Two patients with OC did not receive study drugs because of ineligibility. MTD was defined as BYL719 200mg once daily and olaparib 200mg twice daily. Dose limiting toxicities included hyperglycemia, rash and fever with decreased neutrophil count. Four patients (3 OC and 1 BC) discontinued protocol therapy because of toxicity (2 for hyperglycemia, 1 for nausea and 1 for allergic reaction). Most common toxicities included nausea, hyperglycemia, fatigue, diarrhea and vomiting. At the MTD, 6 patients with OC and 12 patients with BC were enrolled into a dose expansion cohort. The OC expansion cohort has completed enrollment, while the BC cohort is still enrolling. Among patients with OC who received study drugs (28 patients, 26 (93%) with platinum resistant disease), objective response rate (ORR) by RECIST 1.1 was 36% (10/28 patients, all partial responses (PRs)). Median duration of response was 167 days (range 16-398 days); 5 of 10 patients with PR remain on treatment. ORR was 33% for patients with germline BRCA mutations and 31% for patients without germline BRCA mutations. Among patients without germline BRCA mutations with platinum resistant OC, ORR was 29%. Conclusions: Combined BYL719 and olaparib is feasible, and similar clinical benefit was observed in patients with and without germline BRCA mutations. The activity of this combination in OC patients without germline BRCA mutations and with platinum resistant disease was higher than expected from olaparib monotherapy and warrants further investigation. This work was funded in part by the Stand Up To Cancer Ovarian Dream Team. Clinical trial: NCT01623349. Citation Format: Panagiotis A. Konstantinopoulos, William T. Barry, Michael Birrer, Shannon N. Westin, Sarah Farooq, Karen Cadoo, Christin Whalen, Weixiu Luo, Hui Liu, Carol Aghajanian, David B. Solit, Gordon B. Mills, Barry S. Taylor, Helen Won, Michael F. Berger, Sangeetha Palakurthi, Joyce F. Liu, Lew Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D'Andrea, Eric Winer, Gerburg M. Wulf, Ursula A. Matulonis. Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT008. doi:10.1158/1538-7445.AM2017-CT008
Rhinomanometry for Preoperative and Postoperative Assessment of Nasal Obstruction
Gordon, Andrew S.D., McCaffrey, Thomas V., Kern, Eugene B. , Pallanch, John F.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 18, 2017 | Volume: 101 | Issue: 1 | Pages: 20-26

10.1177/019459988910100105 | PMID 2502759 Get It

In this retrospective study we used active, anterior mask rhinomanometric methods to measure nasal resistance before and after surgery for nasal obstruction. The study group comprised 60 patients with nasal obstruction who had 63 preoperative and postoperative rhinomanograms and the control group contained 14 asymptomatic patients who underwent rhinomanometric studies before transnasal, transsphenoidal pituitary surgery. Before surgery the study group had significantly higher total and combined unilateral nasal resistances than either the control group before surgery (p < 0.05 and p < 0.01, respectively) or the study group after surgery (p < 0.0001 for both comparisons). Surgery normalized the nasal resistances of the study group in relation to the control group. A total nasal resistance greater than 1 cm H2O/L/sec or a unilateral resistance greater than 3.5 cm H2O/L/sec suggests clinically significant nasal obstruction. Airway narrowing and obstructive symptoms correlated with airway resistance in the preoperative patient, but symptoms did not correlate well with postoperative resistance.
A Multiethnic Study of the Relationship between Fears and Concerns and Refusal Rates
Verble, Margaret, Bowen, Gordon, Kay, Nancy, Mitoff, Jeffrey, Shafer, Teresa , Worth, Judy, Kay, Nancy

Mayo Clinic

Progress in Transplantation | July 17, 2017 | Volume: 12 | Issue: 3 | Pages: 185-190

10.1177/152692480201200306 | PMID 12371044 Get It

This study builds on previous research that identified fears and concerns heard by procurement coordinators during the donation discussion and that classified those concerns according to the ease with which they can be addressed. In this study, 53 coordinators working for 4 procurement agencies provided data on 323 donation discussions, including fears and concerns expressed by families. The fears and concerns were analyzed by outcome (consent or refusal), race and ethnicity of the family, frequency of reports, and difficulty in addressing. This research confirms many of the findings of the earlier study. The results also indicate that the types of concerns expressed by donor and non–donor families vary somewhat by the family's race and ethnicity. The results can be used to provide training targeted at raising consent rates and to train minority requestors.